A New Jersey appellate court reinstated a lawsuit seeking to force Merck to fund a medical monitoring program for former patients on Vioxx. The screenings are to detect potential heart problems caused by Vioxx. According to the ruling, the decision to dismiss the case was “premature” and did not allow plaintiffs the opportunity to prove legally accepted claims.
You might think that Merck might accept some responsibility for this debacle and support the idea of a medical monitoring program for people who want to get medical attention to make certain they were not injured by Vioxx. Apparently not.